We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 20, 2021

Inhaled and Intranasal Ciclesonide for COVID-19 Treatment in Adult Outpatients

BMJ : British Medical Journal


Additional Info

Disclosure statements are available on the authors' profiles:

BMJ : British Medical Journal
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial
BMJ 2021 Nov 02;375(xx)e068060, N Ezer, S Belga, N Daneman, A Chan, BM Smith, SA Daniels, K Moran, C Besson, LY Smyth, SJ Bartlett, A Benedetti, JG Martin, TC Lee, EG McDonald

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading